iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · IEX Real-Time Price · USD
14.44
-0.57 (-3.80%)
At close: Jul 2, 2024, 4:00 PM
14.72
+0.28 (1.94%)
After-hours: Jul 2, 2024, 4:06 PM EDT
iTeos Therapeutics Revenue
In the year 2023, iTeos Therapeutics had annual revenue of $12.60M, a decrease of -95.29%.
Revenue (ttm)
$12.60M
Revenue Growth
-95.29%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
157
Market Cap
521.61M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 12.60M | -255.04M | -95.29% |
| Dec 31, 2022 | 267.63M | -77.15M | -22.38% |
| Dec 31, 2021 | 344.78M | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 280.83M |
| Paragon 28 | 225.44M |
| SIGA Technologies | 157.02M |
| National Research | 147.42M |
| REGENXBIO | 86.73M |
| IRadimed | 67.69M |
| Contineum Therapeutics | 50.00M |
ITOS News
- 15 days ago - iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer - GlobeNewsWire
- 7 weeks ago - iTeos Therapeutics to raise $120 million via registered direct offering - Invezz
- 7 weeks ago - iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - iTeos Therapeutics Announces $120 Million Registered Direct Offering - GlobeNewsWire
- 3 months ago - iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 4 months ago - iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors - GlobeNewsWire
- 4 months ago - iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire